Table 4.
Metformin use after first estimated glomerular filtration rate (eGFR) decline among metformin initiators with first decline that persisted or worsened within 90 days
| Baseline eGFR, mL/min/1.73 m2 | First eGFR decline, mL/min/1.73 m2 | Northern Denmark, N (%) |
UK, N (%) |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of patients | Number who continued use (%) | Number who discontinued use (%) | Number who switched use (%) | Metformin users who stopped before eGFR decline (%) | Metformin users who stopped before eGFR decline but restarted after eGFR decline | Incomplete follow-up: outcome unknown | Number of patients | Number who continued use (%) | Number who discontinued use (%) | Number who switched use (%) | Metformin users who stopped before eGFR decline | Metformin users who stopped before eGFR decline but restarted after eGFR decline | Incomplete follow-up: outcome unknown (%) | ||
| ≥60 | 45–59 | 1618 | 1139 (70.40) | 115 (7.11) | 20 (1.24) | 236 (14.59) | 80 (4.94) | 28 (1.73) | 2460 | 2083 (84.67) | 160 (6.50) | 47 (1.91) | 103 (4.19) | 41 (1.67) | 26 (1.06) |
| ≥60 | 30–44 | 88 | 51 (57.95) | 7 (7.95) | 4 (4.55) | 14 (15.91) | 3 (3.41) | 9 (10.23) | 149 | 107 (71.81) | 22 (14.77) | 9 (6.04) | 6 (4.03) | 0 | 5 (3.36) |
| ≥60 | 15–29 | 8 | 0 | 1 (12.50) | 0 | 2 (25.00) | 0 | 5 (62.50) | 21 | 6 (28.57) | 7 (33.33) | 3 (14.29) | 0 | 1 (4.76) | 4 (19.05) |
| ≥60 | <15 | 3 | 1 (33.33) | 2 (66.67) | 0 | 0 | 0 | 0 | 2 | 1 (50.00) | 0 | 0 | 0 | 0 | 1 (50.00) |
| 45–59 | 30–44 | 337 | 239 (70.92) | 29 (8.61) | 8 (2.37) | 39 (11.57) | 12 (3.56) | 10 (2.97) | 1414 | 1127 (79.70) | 144 (10.18) | 60 (4.24) | 55 (3.89) | 19 (1.34) | 9 (0.64) |
| 45–59 | 15–29 | 14 | 3 (21.43) | 2 (14.29) | 1 (7.14) | 1 (7.14) | 2 (14.29) | 5 (35.71) | 46 | 26 (56.52) | 12 (26.09) | 2 (4.35) | 3 (6.52) | 0 | 3 (6.52) |
| 45–59 | <15 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 1 (25.00) | 1 (25.00) | 2 (50.00) | 0 | 0 | 0 |
| 30–44 | 15–29 | 77 | 41 (53.25) | 10 (12.99) | 2 (2.60) | 11 (14.29) | 5 (6.49) | 8 (10.39) | 373 | 246 (65.95) | 73 (19.57) | 28 (7.51) | 14 (3.75) | 7 (1.88) | 5 (1.34) |
| 30–44 | <15 | 1 | 0 | 0 | 0 | 0 | 0 | 1 (100.0) | 4 | 1 (25.00) | 1 (25.00) | 0 | 0 | 0 | 2 (50.00) |
| 15–29 | <15 | 8 | 3 (37.50) | 0 | 0 | 4 (50.00) | 0 | 1 (12.50) | 9 | 1 (11.11) | 4 (44.44) | 2 (22.22) | 2 (22.22) | 0 | 0 |